CervoMed (CRVO) Stock Forecast & Price Target

$10.41 -3.88 (-27.15%)

As of 12:22 PM Eastern

CervoMed - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
1

Hold
1

Buy
7

Based on 9 Wall Street analysts who have issued ratings for CervoMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a sell rating, 1 has given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for CRVO.

Consensus Price Target

$27.50
164.17% Upside

According to the 9 analysts' twelve-month price targets for CervoMed, the average price target is $27.50. The highest price target for CRVO is $63.00, while the lowest price target for CRVO is $10.00. The average price target represents a forecasted upside of 164.17% from the current price of $10.41.

Get the Latest News and Ratings for CRVO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CervoMed and its competitors.

CRVO Analyst Ratings Over Time

Type	Current Forecast 3/24/24 to 3/24/25	1 Month Ago 2/23/24 to 2/22/25	3 Months Ago 12/25/23 to 12/24/24	1 Year Ago 3/25/23 to 3/24/24
Strong Buy	2 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)
Hold	1 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$27.50	$37.43	$42.00	$50.00
Forecasted Upside	164.17% Upside	1,541.60% Upside	1,791.89% Upside	128.31% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Buy

Remove Ads

CRVO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRVO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CervoMed Stock vs. The Competition

Type	CervoMed	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.82	2.54
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	92.44% Upside	21,753.34% Upside	18.90% Upside
News Sentiment Rating	Neutral News See Recent CRVO News	Positive News	Positive News

Remove Ads

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/18/2025	Roth Mkm 2 of 5 stars	Boobalan Pachaiyappan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$15.00 ➝ $20.00	+111.24%
3/18/2025	Canaccord Genuity Group 1 of 5 stars	Sumant Kulkarni Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$12.00 ➝ $21.00	+132.04%
3/17/2025	D. Boral Capital 0 of 5 stars	Jason Kolbert Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00	+13.06%
3/13/2025	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Soumit Roy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00	+153.25%
3/13/2025	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Gataulin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$14.00 ➝ $14.00	+126.90%
3/11/2025	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Bussian Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
12/17/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Selvaraju Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
12/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Underweight
12/5/2024	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	B. Pachaiyappan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:30 PM ET.

CRVO Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for CervoMed is $27.50, with a high forecast of $63.00 and a low forecast of $10.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CervoMed in the last year. There is currently 1 sell rating, 1 hold rating, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CRVO shares.
: According to analysts, CervoMed's stock has a predicted upside of 164.17% based on their 12-month stock forecasts.
: Over the previous 90 days, CervoMed's stock had 4 upgrades by analysts.
: CervoMed has been rated by research analysts at Brookline Capital Management, Canaccord Genuity Group, Chardan Capital, D. Boral Capital, Jones Trading, and Roth Mkm in the past 90 days.
: Analysts like CervoMed more than other "medical" companies. The consensus rating score for CervoMed is 2.89 while the average consensus rating score for "medical" companies is 2.82. Learn more on how CRVO compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:CRVO) was last updated on 3/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CervoMed (CRVO) Stock Forecast & Price Target